Orapharma Logo
  • Home
  • Important Safety Information
  • Prescribing Information
  • Loading...
  • Home
  • Important Safety Information
  • Prescribing Information
  • Loading...
hero-bg-arestin
Arestin Logo

Welcome to your 
Elite Experience

Track your progress and maximize your Elite benefits.
View your Dashboard
Real-time insights
Streamlined purchasing
Educational resources
New Discount Tiers
Real-time insights
Streamlined purchasing
Educational resources
New Discount Tiers

Become an Elite member today

Take the first step toward unlocking exclusive perks and premium access. Speak with our team and learn how you can join.

    Get started now
Unlock your Elite Advantages Image
Unlock your Elite Advantages Image
Unlock your Elite Advantages Image

Unlock your Elite Advantages

1

Real-time insights

2

Streamlined purchasing

3

New Discount Tiers

Real-time insights

Our dynamic tracking tools allow you to monitor your Elite Tier with data on purchases, progress, and more.

Show me how the Elite Tiers work

Streamlined purchasing

Easily manage your ARESTIN® (minocycline HCl) Microspheres, 1 mg, orders with a clear, organized view of your past and current purchases, ensuring a smooth ordering process.

New Discount Tiers

We've added new Elite pricing tiers and removed our 'one tier a year' limit, so you can now unlock more discounts with fewer restrictions.

Show me how the Elite Tiers work

Elite Program Breakdown

Here is an overview of the tiers

Elite TierQualifying Volume2025 Box PriceDiscount
Elite 66-11 boxes$6566%
Elite 1212-23 boxes$61412%
Elite 2424-35 boxes$57218%
Elite 3636-47 boxes$53723%
Elite 4848-59 boxes$52325%
Elite 6060-95 boxes$50927%
Elite 9696-119 boxes$49529%
Elite 120120-155 boxes$48131%
Elite 156156-299 boxes$46733%
Elite 300300-499 boxes$45435%
Elite 500500-799 boxes$42639%
Elite 800800-999 boxes$40542%
Elite 10001000+ boxes$39144%

See full Terms & Conditions

background graphic

Bespoke and insightful
data analysis

View your Dashboard
Elite Content image 1Elite Content image 2
In-depth understanding of purchase trends
Streamlined purchasing and goal setting

Unlock your
Elite Advantages

Performance insights

Comprehensive Leaderboard

Monitor the performance of all offices within your network with our comprehensive leaderboard.

For purchasing insights, affiliate offices are displayed by their ARESTIN® (minocycline HCl) Microspheres, 1 mg, purchases - giving you a clear view of how your entire network is addressing periodontal management.

Comprehensive Leaderboard image
Educational content

Access to Educational resources

Explore specialized courses, webinars, and advanced dental techniques with direct access to educational resources. 



Our content is designed to help you develop your professional skills and stay at the forefront of periodontal care.

    Get Started
Access to Educational resources image
background graphic
  • Privacy Policy
  • Legal Notice
  • Cookies Policy
  • Corporate Compliance Information
  • Terms and Conditions
Orapharma Logo
®/TM are trademarks of Bausch Health Companies Inc. or its affiliates. © 2025 Bausch Health Companies Inc. or its affiliates. ARE.0259.USA.24

INDICATION & IMPORTANT SAFETY INFORMATION

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.

WARNINGS AND PRECAUTIONS:

  • ARESTIN should not be used in children, pregnant or nursing women as the use of tetracycline drugs during tooth development may cause permanent discoloration of the teeth.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
  • Hypersensitivity reactions and hypersensitivity syndrome included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.
  • Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy, and malaise. In symptomatic patients, discontinue use of ARESTIN.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.

ADVERSE REACTIONS

The most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Click here for full Prescribing Information.

INDICATION

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1 mg, is indicated as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult periodontitis patients. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.

WARNINGS AND PRECAUTIONS:

  • ARESTIN should not be used in children, pregnant or nursing women as the use of tetracycline drugs during tooth development may cause permanent discoloration of the teeth.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
  • Hypersensitivity reactions and hypersensitivity syndrome included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.
  • Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy, and malaise. In symptomatic patients, discontinue use of ARESTIN.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.

ADVERSE REACTIONS

The most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Click here for full Prescribing Information.